Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.
about
Physiological and pathological implications of 5-hydroxymethylcytosine in diseasesNew nucleoside analogs for patients with hematological malignancies.Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.Use of clofarabine for acute childhood leukemia.Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemiaDiastereoselective self-assembly of clofarabine lipids
P2860
Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Clofarabine as a novel nucleos ...... action and clinical activity.
@ast
Clofarabine as a novel nucleos ...... action and clinical activity.
@en
Clofarabine as a novel nucleos ...... action and clinical activity.
@nl
type
label
Clofarabine as a novel nucleos ...... action and clinical activity.
@ast
Clofarabine as a novel nucleos ...... action and clinical activity.
@en
Clofarabine as a novel nucleos ...... action and clinical activity.
@nl
prefLabel
Clofarabine as a novel nucleos ...... action and clinical activity.
@ast
Clofarabine as a novel nucleos ...... action and clinical activity.
@en
Clofarabine as a novel nucleos ...... action and clinical activity.
@nl
P2093
P1476
Clofarabine as a novel nucleos ...... action and clinical activity.
@en
P2093
Anna Korycka
Ewa Lech-Maranda
Tadeusz Robak
P304
P356
10.2174/138955709788452586
P577
2009-06-01T00:00:00Z